|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0006826,
umls-concept:C0008838,
umls-concept:C0008976,
umls-concept:C0013089,
umls-concept:C0015133,
umls-concept:C0016360,
umls-concept:C0023413,
umls-concept:C0024623,
umls-concept:C0025677,
umls-concept:C0029246,
umls-concept:C0034656,
umls-concept:C0035168,
umls-concept:C0087111,
umls-concept:C0205088,
umls-concept:C0205179,
umls-concept:C0239307,
umls-concept:C0282461,
umls-concept:C0685938,
umls-concept:C1274040,
umls-concept:C1521808,
umls-concept:C1705294
|
|
pubmed:issue |
14
|
|
pubmed:dateCreated |
2000-8-1
|
|
pubmed:abstractText |
To compare the efficacy and tolerability of etoposide, leucovorin, and bolus fluorouracil (ELF) or infusional fluorouracil plus cisplatin (FUP) with that of the reference protocol of fluorouracil, doxorubicin, and methotrexate (FAMTX) in advanced gastric cancer.
|
|
pubmed:grant |
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
0732-183X
|
|
pubmed:author |
pubmed-author:BaronBB,
pubmed-author:BleibergHH,
pubmed-author:BodensteinHH,
pubmed-author:CouvreurM LML,
pubmed-author:DucreuxM PMP,
pubmed-author:LacaveA JAJ,
pubmed-author:NordlingerBB,
pubmed-author:PaillotBB,
pubmed-author:PiedboisPP,
pubmed-author:PlankerMM,
pubmed-author:RougierPP,
pubmed-author:SantosJ GJG,
pubmed-author:SchmollH JHJ,
pubmed-author:Van CutsemEE,
pubmed-author:VanhoeferUU,
pubmed-author:WilkeHH,
pubmed-author:WilsJ AJA
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
18
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2648-57
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:10894863-Adenocarcinoma,
pubmed-meshheading:10894863-Adult,
pubmed-meshheading:10894863-Aged,
pubmed-meshheading:10894863-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:10894863-Cisplatin,
pubmed-meshheading:10894863-Doxorubicin,
pubmed-meshheading:10894863-Etoposide,
pubmed-meshheading:10894863-Female,
pubmed-meshheading:10894863-Fluorouracil,
pubmed-meshheading:10894863-Humans,
pubmed-meshheading:10894863-Leucovorin,
pubmed-meshheading:10894863-Levoleucovorin,
pubmed-meshheading:10894863-Male,
pubmed-meshheading:10894863-Methotrexate,
pubmed-meshheading:10894863-Middle Aged,
pubmed-meshheading:10894863-Proportional Hazards Models,
pubmed-meshheading:10894863-Stomach Neoplasms,
pubmed-meshheading:10894863-Survival Analysis
|
|
pubmed:year |
2000
|
|
pubmed:articleTitle |
Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group.
|
|
pubmed:affiliation |
Department of Internal Medicine (Cancer Research), West German Cancer Center, University of Essen Medical School, Essen, Germany.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Research Support, U.S. Gov't, P.H.S.,
Randomized Controlled Trial,
Multicenter Study,
Clinical Trial, Phase III
|
